advertisement

---

Biomolecules 16

Showing records 1 to 16 | Display all abstracts in Biomolecules

99229 Leukotriene Signaling as a Target in α-Synucleinopathies
Strempfl K
Biomolecules 2022; 12:

---

98932 Systemic Treatment with Pioglitazone Reverses Vision Loss in Preclinical Glaucoma Models
Zeng H
Biomolecules 2022; 12:

---

98931 Advances in Ophthalmic Optogenetics: Approaches and Applications
Prosseda PP
Biomolecules 2022; 12:

---

98932 Systemic Treatment with Pioglitazone Reverses Vision Loss in Preclinical Glaucoma Models
Dumitrescu AV
Biomolecules 2022; 12:

---

99229 Leukotriene Signaling as a Target in α-Synucleinopathies
Unger MS
Biomolecules 2022; 12:

---

98931 Advances in Ophthalmic Optogenetics: Approaches and Applications
Tran M
Biomolecules 2022; 12:

---

98932 Systemic Treatment with Pioglitazone Reverses Vision Loss in Preclinical Glaucoma Models
Wadkins D
Biomolecules 2022; 12:

---

98931 Advances in Ophthalmic Optogenetics: Approaches and Applications
Kowal T
Biomolecules 2022; 12:

---

99229 Leukotriene Signaling as a Target in α-Synucleinopathies
Flunkert S
Biomolecules 2022; 12:

---

98932 Systemic Treatment with Pioglitazone Reverses Vision Loss in Preclinical Glaucoma Models
Elwood BW
Biomolecules 2022; 12:

---

99229 Leukotriene Signaling as a Target in α-Synucleinopathies
Trost A
Biomolecules 2022; 12:

---

98931 Advances in Ophthalmic Optogenetics: Approaches and Applications
Wang B; Sun Y
Biomolecules 2022; 12:

---

98932 Systemic Treatment with Pioglitazone Reverses Vision Loss in Preclinical Glaucoma Models
Gramlich OW
Biomolecules 2022; 12:

---

99229 Leukotriene Signaling as a Target in α-Synucleinopathies
Reitsamer HA; Hutter-Paier B
Biomolecules 2022; 12:

---

98932 Systemic Treatment with Pioglitazone Reverses Vision Loss in Preclinical Glaucoma Models
Kuehn MH
Biomolecules 2022; 12:

---

99229 Leukotriene Signaling as a Target in α-Synucleinopathies
Aigner L
Biomolecules 2022; 12:

---